Antimicrobial Activity Assay of Liposomal Lipopolysaccharide Extracted from Escherichia coli

Document Type : Original Articles


University of Kufa, Faculty of Science, Najaf, Iraq


Escherichia coli (E. coli) is a bacterial bacillus known to be negative for the gram dye, and it is part of the normal flora inside the human body. The current study aimed to investigate the possibility of using lipopolysaccharides (LPS) as an antimicrobial agent. A total of 30 isolates of E. coli were collected from 100 specimens of urine isolated from patients with recurrent urinary tract infections (UTIs) referring to Al-Sadr Teaching Hospital. The samples were cultured on identification media; thereafter, they were diagnosed according to the phenotypic form, biochemical tests, and finally by VITK-2. The results of the prevalence of E. coli isolates illustrated that from 30 isolates of E. coli which were collected from 100 urine specimens, 14 (46.6%), 6 (20%), and 10 (33.3%) cases belonged to the urinary tract infections, kidney stones, and urinary catheter samples, respectively. The isolates displayed multiple drug resistance (MDR) to most of the antibiotics used in the study. Therefore, the lipopolysaccharide extracted from E. coli was used as an antimicrobial agent. The recorded data obtained from the polymerase chain reaction (PCR) for WaaA, WaaC, wamB, and wabG genes demonstrated that the isolates possessed biosynthesis genes for LPS. The results indicated that LPS at concentrations of 150, 250, and 500 μg/ml has as an anti-growth agent for Klebsiella pneumonia, Proteus mirabilis, Salmonella typhi, Pseudomonas aeruginosa, Bacillus subtilis, Staph aureus, and candida albicans. The highest inhibitory effect was observed on K. pneumonia, P. mirabilis, S. typhi, B. subtilis, and C. albicans, as compared to the control antimicrobials agents (Amoxicillin, Nystatin). The LPS loaded on liposome nanoparticles can open new horizons in medicine by its inclusion in the manufacture of broad-spectrum antibiotics.


Main Subjects

  1. Nataro JP, Kaper JB. Diarrheagenic escherichia coli. Clin Microbiol Rev. 1998;11(1):142-201.
  2. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015;373(5):415-27.
  3. Sligl W, Taylor G, Brindley PG. Five years of nosocomial Gram-negative bacteremia in a general intensive care unit: epidemiology, antimicrobial susceptibility patterns, and outcomes. Int J Infect Dis. 2006;10(4):320-5.
  4. Khalid S, Piggot TJ, Samsudin F. Atomistic and coarse grain simulations of the cell envelope of Gram-negative bacteria: what have we learned? Acc Chem Res. 2018;52(1):180-8.
  5. Wang X, Quinn PJ. Lipopolysaccharide: biosynthetic pathway and structure modification. Prog Lipid Res. 2010;49(2):97-107.
  6. Goto Y, Kiyono H. Epithelial barrier: an interface for the cross‐communication between gut flora and immune system. Immunol Rev. 2012;245(1):147-63.
  7. Dharmadhikari S, Peshwe S. Molecular level studies on multiple antibiotic and serum resistance in UTI pathogens. Indian J Biotechnol. 2009;8(1).
  8. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell.2007;128(4):707-19.
  9. Joshi RM, Albert MJ. Hybrid ELtor Vibrio cholerae O1. JEmerg Infect. 2009;11:1879-80.
  10. Nile R, Darweesh MF, Al-Rufaie MM. Liposomal-lipopolysaccharide vaccine extracted from Proteus mirabilis induces moderate TLR4 and CD14 production. Curr Issues Pharm Med Sci. 2019;32:81-6.
  11. Chandan V, Fraser AD, Brooks BW, Yamazaki H. Simple extraction of Campylobacter lipopolysaccharide and protein antigens and production of their antibodies in egg yolk. Int J Food Microbiol. 1994;22(2-3):189-200.
  12. Dubois M, Gilles KA, Hamilton JK, Rebers Pt, Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem. 1956;28(3):350-6.
  13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72(1-2):248-54.
  14. Mohammed S, Redeiny R. Anticancer Activity Assay of Nano-Fractional Compounds that Purified from Soil Actinomycetes. Archives of Ecotoxicology. 2021;3:32-8.
  15. Kavanagh F. Analytical microbiology: Elsevier; 2014.
  16. De Francesco MA, Ravizzola G, Peroni L, Negrini R, Manca N. Urinary tract infections in Brescia, Italy: etiology of uropathogens and antimicrobial resistance of common uropathogens. Med Sci Monit. 2007;13(6):136-44.
  17. Daoud Z, Salem Sokhn E, Masri K, Cheaito K, Haidar-Ahmad N, Matar GM, et al. Escherichia coli isolated from urinary tract infections of Lebanese patients between 2005 and 2012: epidemiology and profiles of resistance. Front Med. 2015;2:26.
  18. Kaszowska M, Mendoza-Barberá D, Maciejewska A, Merino S, Lugowski C, Tomás JM. The complete structure of the core oligosaccharide from Edwardsiella tarda EIB 202 lipopolysaccharide. Int J Mol Sci. 2017;18(6):1163.
  19. Zuhir R, Alaubydi MAS. Extraction and partial purification of lipopolysaccharide from clinical Proteus mirabilis isolate and compared with standard bacteria. Iraqi J Sci. 2016;57(1C):599-608.
  20. Yossef HS. Enhancement of Pro-inflammatory Cytokine by Partial Purified Lipopolysaccharide Extracted from Invasive Klebsiella Pneumoniae. Al-Nahrain J Sci. 2014;17(3):111-5.
  21. Al-Azawy SJ, Abdullah AH. Study the inhibitory effect of purified lipopolysaccharide extracted from Proteus mirabilis on E. coli O157 H7 isolate from diarrheal infected animals. Diyala J Pure Sci. 2017;13(2 -part 2):282-95.
  22. Steimle A, Autenrieth IB, Frick J-S. Structure and function: Lipid A modifications in commensals and pathogens. Int J Med Microbiol. 2016;306(5):290-301.
  23. Wu EL, Engström O, Jo S, Stuhlsatz D, Yeom MS, Klauda JB, et al. Molecular dynamics and NMR spectroscopy studies of E. coli lipopolysaccharide structure and dynamics. Biophys J. 2013;105(6):1444-55.
  24. Lerouge I, Vanderleyden J. O-antigen structural variation: mechanisms and possible roles in animal/plant–microbe interactions. FEMS Microbiol Rev. 2002;26(1):17-47.
  25. Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A. Design of liposomal formulations for cell targeting. Colloids and surfaces B: Biointerfaces. 2015;136:514-26.
  26. Bulbake U, Doppalapudi S, Kommineni N, Khan Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12.
  27. Moyá ML, López-López M, Lebrón JA, Ostos FJ, Pérez D, Camacho V, et al. Preparation and characterization of new liposomes. Bactericidal activity of cefepime encapsulated into cationic liposomes. Pharmaceutics. 2019;11(2):69.
  28. Torres IMS, Bento EB, Almeida LdC, Sá LZCMd, Lima EM. Preparation, characterization and in vitro antimicrobial activity of liposomal ceftazidime and cefepime against Pseudomonas aeruginosa strains. Braz J Microbiol. 2012;43(3):984-92.